RE: Shameful Promotion of this share13 Jun 2022 17:21
Share price movement
The Board of SkinBioTherapeutics plc ( AIM: SBTX or the "Company") notes the recent share price movement and confirms that it is not aware of any material commercial or operational reason that might be the cause.
The Company's position on sales of its first commercial product AxisBiotix-Ps(R) was outlined in the Interim Results dated 29 March 2022 where management acknowledged slower uptake than originally anticipated, and that it was not possible to predict the quantum impact on sales.
The team continues to focus on driving sales of AxisBiotix-Ps(R). The marketing and advertising campaign is now very active, using influencers who have psoriasis themselves for the digital campaign and advertising in regional and national newspapers such as the Mail, Telegraph and Metro. The product continues to receive very positive customer feedback and the subscriber retention rate is now >80%.
Other pillars of the business, including work with Croda/Sederma are progressing accordingly to plan.
As always, the Company will continue to inform the market should there be additional news flow.